KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Operating Expenses (2016 - 2025)

Inovio Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $21.2 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 22.44% year-over-year to $21.2 million; the TTM value through Sep 2025 reached $89.9 million, down 24.85%, while the annual FY2024 figure was $112.6 million, 22.21% down from the prior year.
  • Operating Expenses for Q3 2025 was $21.2 million at Inovio Pharmaceuticals, down from $23.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $106.3 million in Q4 2021 and bottomed at $20.5 million in Q4 2024.
  • The 5-year median for Operating Expenses is $37.3 million (2023), against an average of $47.8 million.
  • The largest annual shift saw Operating Expenses surged 204.55% in 2021 before it plummeted 64.48% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $106.3 million in 2021, then tumbled by 47.28% to $56.1 million in 2022, then tumbled by 50.96% to $27.5 million in 2023, then dropped by 25.49% to $20.5 million in 2024, then rose by 3.53% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Operating Expenses are $21.2 million (Q3 2025), $23.1 million (Q2 2025), and $25.1 million (Q1 2025).